Abstract
3556Background: Apatinib, an oral VEGFR2 inhibitor, has been approved as third line treatment for metastatic gastric cancer in China. The aim of this study was to evaluate the efficacy and safety o...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
